Access Presentation (15 min plus Q&A - note: due to a technical issue the recording begins at bullet point 3 on slide 1)
Results of the BMT CTN Protocol 0201 PBSC versus Marrow study were presented during the Plenary session at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego. This randomized, multicenter, phase III trial compared survival rates for patients receiving PBSC with patients receiving bone marrow.
This session will provide a second opportunity to hear the ASH presentation and learn about the results of this important study.
Dennis Confer, M.D.
Chief Medical Officer
National Marrow Donor Program
- Summarize the outcomes associated with use of PBSC and marrow stem cell sources in patients who receive a transplant from an unrelated donor.
- Identify potential changes to current practice for patients who receive PBSC and marrow stem cells from an unrelated donor.
At the conclusion of this session participants will have greater understanding of the outcomes of PBSC versus marrow stem cells in unrelated donor transplant and a comparison of complications related to either cell source.
This activity is intended for Medical Directors, physicians, coordinators and other staff involved in unrelated donor transplantation and donor center staff.
If you have any questions regarding this program, call Renee Ryan at (800) 526-7809 ext. 8430, or e-mail firstname.lastname@example.org.